2008•DARU Journal of Pharmaceutical SciencesRequires access

Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARSTM) in patients with diabetic foot ulcer: A Phase I clinical trial

Ramin Heshmat, K Mohammad, M R Mohajeri Tehrani, Abbasali Keshtkar, F Gharib Doust, Ardeshir Larijani Mohammad Bagher

Open publisher page 17 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Diabetes mellitus, Clinical trial, Toxicity, Drug, Adverse effect, Side effect (computer science), Surgery

Back to paper search Browse research topics Original source

Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARSTM) in patients with diabetic foot ulcer: A Phase I clinical trial — Research Paper | ScholarLens